Treatment comparisons | Number of studies | Pairwise meta-analysis Odds ratio (95% CI) | P value | Heterogeneity I2, % (variation in OR attributable to heterogeneity) |
---|---|---|---|---|
cSSSI | ||||
 Vancomycin vs Oritavancin | 2 | 0.96 (0.59, 1.56) | 0.867 | 0.0 |
 Vancomycin vs Daptomycin | 4 | 1.04 (0.79, 1.36) | 0.756 | 0.0 |
 Vancomycin vs Telavancin | 4 | 0.86 (0.61, 1.24) | 0.430 | 0.0 |
 Vancomycin vs Tigecycline | 3 | 1.15 (0.79, 1.66) | 0.451 | 0.0 |
 Vancomycin vs Ceftaroline | 4 | 0.94 (0.71, 1.26) | 0.695 | 0.0 |
 Vancomycin vs Dalbavancin | 2 | 1.00 (0.77, 1.31) | 0.973 | 0.0 |
 Vancomycin vs Ceftobiprole | 2 | 0.78 (0.33, 1.82) | 0.565 | 0.0 |
 Linezolid vs Vancomycin | 5 | 1.23 (1.09, 1.50) | 0.006 | 0.0 |
 Linezolid vs Dalbavancin | 1 | 0.84 (0.39, 1.82) | 0.673 | – |
 Linezolid vs SXT/rifampicin | 1 | 0.70 (0.16, 2.95) | 0.627 | – |
 Linezolid vs Omadacycline | 1 | 0.36 (0.03, 4.18) | 0.417 | – |
 Linezolid vs Fusidic Acid | 1 | 2.71 (0.83, 8.89) | 0.099 | – |
 Linezolid vs JNJ-Q2 | 1 | 0.95 (0.45, 1.94) | 0.682 | – |
 Linezolid vs Tedizolid | 2 | 1.09 (0.58, 2.02) | 0.780 | 0.0 |
 Linezolid vs Teicoplanin | 1 | 0.52 (0.15, 1.79) | 0.234 | – |
HAP/VAP | ||||
 Vancomycin vs Telavancin | 2 | 1.02 (0.85, 1.23) | 0.822 | 0.0 |
 Vancomycin vs Vancomycin/rifampicin | 1 | 1.49 (0.72, 3.06) | 0.278 | – |
 Vancomycin vs Quinupristin/dalfopristin | 1 | 1.03 (0.71, 1.51) | 0.858 | – |
 Linezolid vs Vancomycin | 8 | 1.11 (0.91, 1.34) | 0.301 | 0.0 |
 Linezolid vs Ceftobiprole | 1 | 0.53 (0.17, 1.57) | 0.251 | – |
 Linezolid vs Teicoplanin | 1 | 0.38 (0.07, 2.16) | 0.279 | – |
 Linezolid vs SXT/rifampicin | 1 | 1.77 (0.25, 12.45) | 0.562 | – |